Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

17.50
-0.0700-0.40%
Post-market: 17.500.00000.00%19:59 EDT
Volume:2.55M
Turnover:44.42M
Market Cap:1.85B
PE:-13.30
High:17.76
Open:17.75
Low:17.21
Close:17.57
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:1.19
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.21
PE(LYR):-2.45

Loading ...

Sarepta Grants 211,070 Inducement RSUs to 37 New Hires Under 2024 Incentive Plan

Reuters
·
Oct 01

Sarepta Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Oct 01

Sarepta Says Elevidys Shows 2-Year Functional Gains in 8-12-Year-Old Duchenne Patients Versus External Controls at WMS 2026

Reuters
·
Sep 30

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of Elevidys (Delandistrogene Moxeparvovec) in Older Ambulatory Patients with Duchenne

THOMSON REUTERS
·
Sep 30

Sarepta Therapeutics, Inc. : JP Morgan Cuts Target Price to $20 from $23

THOMSON REUTERS
·
Sep 30

Sarepta to Present 3-Year Embark Trial Data for Elevidys Gene Therapy in Duchenne Muscular Dystrophy at WMS 2026

Reuters
·
Sep 25

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

THOMSON REUTERS
·
Sep 25

Sarepta Posts First Phase 4 Endure Real-World Safety Data for Elevidys in Duchenne Patients at NMSG 2026

Reuters
·
Sep 24

Stoke Therapeutics Names Solid Biosciences CEO Bo Cumbo to Board

Reuters
·
Sep 24

Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone

TIPRANKS
·
Sep 09

H.C. Wainwright reiterates Sell on Sarepta after Novartis study miss

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Sarepta Therapeutics Down 11.4%, Dyne Therapeutics Down 22%

THOMSON REUTERS
·
Sep 08

Sarepta Therapeutics Announces Recipients of Route 79, the Duchenne Scholarship Program, for the 2026-2027 Academic Year

THOMSON REUTERS
·
Sep 08

Sarepta, Dyne Sink After Novartis Muscle Disorder Trial Failure

Reuters
·
Sep 08

Sarepta Therapeutics Down 15.6%, Dyne Therapeutics Down 29%

THOMSON REUTERS
·
Sep 08

Shares of Some Drug Developers Fall Premarket After Novartis Late-Stage Muscle Disorder Trial Fails

THOMSON REUTERS
·
Sep 08

Novartis Twin Drug Setbacks Pile Pressure on Pipeline, CEO

Reuters
·
Sep 08